Abstract To compare the effectiveness of breast-conserving therapy (BCT) and mastectomy, all women aged B40 years, treated for early-stage breast cancer in the southern part of the Netherlands between 1988 and 2005, were identified. A total of 562 patients underwent mastectomy and 889 patients received BCT. During follow-up, 23 patients treated with mastectomy and 135 patients treated with BCT developed a local relapse without previous or simultaneous evidence of distant disease. The local relapse risk for patients treated with mastectomy was 4.4% (95% confidence interval (CI) 2.4-6.4) at 5 years and reached a plateau after 6 years at 6.0% (95% CI 3.5-8.5). After BCT, the 5-, 10-and 15-year risks were 8.3% (95% CI 6.3-10.5), 18.4% (95% CI 15.0-21.8) and 28.2% (95% CI 23.0-33.4), respectively (P \ 0.0001). Adjuvant systemic therapy following BCT reduced the 15-year local relapse risk from 32.9% (95% CI 26.7-39.1) to 16.1% (95% CI 9.1-23.1), (P = 0.0007). In conclusion, local tumor control in young patients with early-stage breast cancer is worse after BCT than after mastectomy. Adjuvant systemic therapy significantly improves local control following BCT and also for that reason it should be considered for most patients B40 years. Long-term follow-up is highly recommended for young patients after BCT, because even with systemic treatment an annual risk of local relapse of 1% remains up to 15 years after treatment.
Introduction
Multiple randomized controlled trials have shown that survival rates for patients with early-stage breast cancer are comparable after breast-conserving therapy (BCT) and mastectomy [1] [2] [3] [4] [5] . Consequently, BCT is now widely accepted as a local treatment for early-stage breast cancer.
Some doubts still remain concerning the treatment of young women since young age has been shown to be an independent risk factor for local relapse after BCT, much more than after mastectomy [6] [7] [8] [9] [10] . The 10-year local relapse rate for women aged B40 years varies between 19 and 35% after BCT and between 7 and 12% after mastectomy [6, 8, 9, 11, 12] . In two previous reports concerning women B40 years we found 5-and 10-year actuarial local relapse rates of 9 and 17.9%, respectively, after BCT [13] and of 5.6 and 7.3% after mastectomy [14] .
Only 5-10% of all women with breast cancer are aged 40 years or younger at diagnosis. Because of this relatively low incidence, subgroup analyses of the randomized controlled trials could not confirm whether BCT is as safe as mastectomy in the treatment of early-stage breast cancer in young women. Even by pooling data derived from all available trials, the number of young patients would be too small to draw firm conclusions. Therefore, evidence for the safety of BCT was searched in a few non-randomized studies [15] [16] [17] . Limitations of these studies are the relatively small number of patients, ranging from 540 to 668, insufficient information on the risk factors of local relapse and a follow-up time limited to only 10 years. Therefore, we evaluated a large cohort of 1,451 patients aged B40 years with a sufficiently long follow-up to determine treatment results up to 15 years.
Patients and methods

Patients
Patient data were obtained from the population-based Eindhoven Cancer Registry (ECR). This serves a population of approximately 2.4 million inhabitants in the south of the Netherlands and records data on all patients with newly diagnosed cancer since 1955. These data were compared to data derived from the two radiotherapy departments in this region, the Catharina Hospital in Eindhoven and the Dr. Bernard Verbeeten Institute in Tilburg. Records of patients who did not receive radiotherapy after mastectomy were provided by the surgical departments of the ten regional hospitals.
Only patients with stage I or II breast cancer (pT1-2, N0-2, M0) were considered eligible for the study. The ECR identified 846 patients aged B40 years that underwent mastectomy between 1988 and 2005, from whom 745 medical records were available. For the other 101 patients records were either missing or incomplete after digitalising paper medical records. Over the same period, 937 patients aged B40 years received BCT, for whom all patient records were available. The medical files were reviewed to extract information with respect to patient, tumor and treatment characteristics as well as to outcome. After exclusion of 122 patients with stage III or IV breast cancer, 44 patients with neo-adjuvant systemic treatment, 8 patients with synchronous bilateral breast cancer, 19 patients with non-invasive breast cancer, and 8 patients without radiotherapy of the breast following breast-conserving surgery, 562 patients remained available for analysis in the mastectomy group and 889 patients in the BCT group.
Treatment
Patients underwent mastectomy or BCT. All patients received either a sentinel lymph node procedure or an axillary lymph node dissection. Indications for locoregional radiotherapy after mastectomy included an involved lymph node in the apex of the axilla, fixed axillary lymph nodes or C4 lymph node metastases. This locoregional radiotherapy was given to a dose of 46-50 Gy. In case of an incomplete tumor resection of the primary breast tumor, a boost to a dose of 13.8-26 Gy was given to part of the chest wall. Until 2002 the guidelines also recommended the use of postmastectomy radiotherapy for patients with extracapsular lymph node invasion. In the framework of BCT, patients received 46-50 Gy to the whole breast, in 796 patients (91.8%) followed by a boost of 10-26 Gy to the primary tumor bed. Indications for locoregional radiotherapy after breast-conserving surgery were similar to those after mastectomy.
Before 1998, adjuvant systemic treatment was based on regional guidelines and was recommended only for patients with involved axillary lymph nodes. In 1998, a new national guideline was published [18] , based on the St. Gallen guidelines [19, 20] , after which lymph node-negative patients with high-risk breast cancer were advised to receive adjuvant systemic treatment, depending on size, grade, and hormone receptor status of the tumor. In 2001, the guidelines were updated, recommending adjuvant systemic treatment also for most patients aged B35 years, irrespective of their lymph node status.
The standard chemotherapy regimen consisted of cyclophosphamide, methotrexate and fluorouracil (CMF) in the early years of the study period and of anthracyclinecontaining regimens thereafter. From 1988 until 2001 there was no strict guideline for the use of hormonal therapy for pre-menopausal patients who had receptor-positive tumors.
After 2001 hormonal therapy was recommended for all receptor-positive high-risk patients. In the study period, trastuzumab was not yet implemented in the adjuvant setting.
Follow-up
For patients treated with mastectomy, follow-up was completed until 1st January 2007 or death. Median duration of follow-up was 7.4 years. Patients receiving BCT were followed up until death or 1st January 2008. Median duration of follow-up was 9.5 years. Seventy-three patients (5.0%) were lost to follow-up, meaning that their last contact with the surgeon, radiation oncologist or general practitioner was before 1st January 2007 in case of mastectomy or 1st January 2008 in case of BCT. The median follow-up for these patients was 8.9 years and they have been included in the analysis until their last date of contact.
Methods
The endpoints of this study were local relapse, distant recurrence and death.
Local relapse was defined as reappearance of tumor growth in the treated breast or overlying skin or, in case of mastectomy, on the ipsilateral chest wall. The time to an event was estimated using the life-table method and was considered to be the interval between the date of primary treatment and occurrence of the event. Observation time was censored at 1st January 2007 for patients undergoing mastectomy and 1st January 2008 for those undergoing BCT, or death or the last date of contact for patients who were lost to follow-up. Local relapses that were diagnosed after distant metastases or with synchronous distant disease were not counted as events in the survival analyses, because these are considered to be of little clinical importance and because the risk of underreporting is high. These patients were censored at the date of diagnosis of distant disease.
A multivariate analysis was carried out using Cox proportional hazard model to determine the impact of the type of surgery on the risk of distant recurrence, adjusting for age at diagnosis, the period of diagnosis, tumor size, axillary nodal status and use of adjuvant systemic treatment.
Results
Patient, tumor and treatment characteristics Table 1 lists the patient, tumor and treatment characteristics of the study population. Median age at diagnosis was 37.2 years for patients treated with mastectomy and 37.4 years for those treated with BCT. As expected, despite the restriction to earlystage breast cancer, patients treated with mastectomy generally had worse prognostic factors, when compared to those treated with BCT (Table 1) . Because of worse prognostic factors, patients treated with mastectomy more often received systemic therapy (P \ 0.0001). The proportion of young women undergoing BCT decreased from 69% in the period 1988-1993 to 55% in the period 2000-2005 (P \ 0.0001).
After mastectomy, 37% of the patients received radiotherapy. The overall proportion of patients aged B40 years receiving adjuvant systemic treatment increased from 35% in the period 1988-1993 to 77% in the period 2000-2005 (Fig. 1) .
Local tumor control
Of the 131 local relapses occurring after BCT, 61 (45%) were diagnosed within 5 years, 44 (33%) between 5 and 10 years, and 30 (22%) thereafter. Twenty-three local relapses occurred after mastectomy, of which 19 (83%) within 5 years and 4 (17%) between 5 and 10 years after treatment. No local relapses were diagnosed more than 6 years after mastectomy.
Of the local relapses after BCT, 19 (14%) were in situ and 111 (82%) were invasive tumors. For five patients this information was missing. Of the 23 local relapses after mastectomy, 22 were invasive and one was an in situ lesion. Ninety (67%) of the 135 local relapses following BCT were localized at or near the site of the primary tumor, 15 (11%) were localized elsewhere in the breast, seven (5%) were diffuse and one involved the skin. For 22 patients information on the location of the local relapse was missing.
The actuarial risk of local relapse was significantly higher for patients undergoing BCT compared to patients undergoing mastectomy (Fig. 2a) . The 5-, 10-and 15-year local relapse rates were 8.3% (95% CI 6.3-10.5), 18.3% (95% CI 14.9-21.7) and 27.9% (95% CI 22.9-32.9), respectively. For the patients who underwent mastectomy, these figures were 4.4% (95% CI 2.4-6.4) after 5 years and 6.0% (95% CI 3.5-8.5) after 10 and after 15 years of follow-up. When also taking into account the local relapses that occurred simultaneously with distant metastases (11 after mastectomy and 19 after BCT), the 5-, 10-and 15-year rates were 10.3% (95% CI 8.1-12. A significant improvement was observed in the local control rate after BCT during the study period (Table 2) . A stratified analysis according to axillary nodal status showed that this improvement did only occur in patients with negative lymph nodes. This appeared to be related to the increased use of systemic therapy over the years, as the risk for local relapse was significantly lower for patients who received adjuvant systemic treatment (Table 2 ; Fig. 2b) . A higher local relapse risk was observed for patients whose excision of the primary tumor was incomplete or doubtful, as compared to those with a complete excision ( Table 2) . No significant associations were found between the risk of local relapse after BCT and tumor size and between the different age groups (\30, 30-35 and 35-40 years) ( Table 2 ). The local relapse rate was significantly higher after BCT in the patient group without a boost dose of radiotherapy to the tumor bed (Table 2) . No dose-effect relationship was observed for the patients receiving a boost dose.
Distant recurrence-free and overall survival No statistically significant difference in distant recurrencefree survival was observed between the patients undergoing BCT or mastectomy (Fig. 3) . The 10-year distant recurrence-free survival rates were 71.0% (95% CI 67.6-74.4) and 67.0% (95% CI 62.4-71.6), respectively. The 10-year overall survival rate was 74.9% (95% CI 71.7-78.1) after BCT and 71.2% (95% CI 66.4-76.0) after mastectomy (P = 0.215). A stratified analysis according to tumor size (pT1 or pT2) and nodal status (pN0 and pN1-2) was performed, in which four strata were created: pT1-pN0, pT2-pN0, pT1-pN1-2 and pT2-pN1-2. In none of these four strata a statistically significant difference was observed in the distant recurrence-free survival between the patients undergoing BCT versus those with mastectomy, with P values of 0.52, 0.17, 0.72 and 0.64, respectively.
In the first 7 years after treatment, distant recurrence risk was significantly lower for the patients treated with BCT (P = 0.009). However, for the patients surviving without distant metastases until the seventh year of followup, the risk of developing distant disease is lower for the patients with mastectomy (P = 0.044). This reversal of the risk was also expressed by the distant disease hazard ratio (HR) for BCT compared to mastectomy, which was 0.75 (95% CI 0.61-0.93) during the first 7 years of follow-up and 1.96 (95% CI 1.02-3.76) for the patients followed from 7 years onward until censoring.
A significant improvement in the distant recurrence-free survival was observed during the study period (Fig. 3) . The 5-year distant recurrence-free survival improved from 72.2% (95% CI 67.9-76.5) in the period 1988-1993 to 84.8% (95% CI 81.0-88.6) in the period 2000-2005 (HR 0.61 (95% CI 0.45-0.82)) ( Table 3 ). Other independent favorable prognostic factors were: a negative axillary nodal status, a tumor size of 2 cm or less and the use of adjuvant systemic treatment.
Also the multivariate analysis showed no statistically significant difference in distant recurrence-free survival between patients treated with BCT and mastectomy (HR, 0.97; 95% CI 0.78-1.20).
Discussion
The current study is one of the few studies focussing on young women with early-stage breast cancer, comparing local control and survival after BCT and mastectomy. Our results indicate a worse local control after BCT with a linearly increasing cumulative risk of developing a local relapse even after more than 15 years of follow-up, whereas a plateau was reached after 6 years for the patients treated with mastectomy. Despite the more favorable stage distribution of the patients who underwent BCT, distant disease-free survival at 10 years was similar for both treatment groups. The local relapse rate after BCT showed a decreasing trend during the study period but still remains at 1% annually for the patients treated in the period 2000-2005. We also noted a significant decrease of the distant recurrence risk over time, associated with increased use of systemic therapy, irrespective of the type of surgery.
Many studies on BCT have shown that young women have an increased local relapse risk compared to older women [6] [7] [8] [9] [10] 21] . However, few data are available from studies in young women on treatment outcomes after BCT compared to mastectomy. Our data show that local relapses keep on occurring after BCT, even after prolonged followup. This continuing risk was previously reported by Kreike et al. [22] who report 10-and 15-year local relapse rates of 9.3 and 13.8%, respectively, in a cohort of 1,024 patients with a mean age of 50 years. A possible explanation for at least part of the late local relapses is the occurrence of new primary tumors.
Minimizing the risk of local relapse remains an important clinical issue. The EBCTCG meta-analysis has shown that local control has an influence on long-term breast 404  363  259  178  117  75  51  31  17  7  BCT without ST 483  432  360  304  249  194  150  96  57  33  MAS with ST  363  286  186  117  75  56  37  19  8  2  MAS without ST 198  173  145  122  99  75  55  38  15  3 Number of patients at risk cancer-related mortality: for every 4 local relapses prevented at 5 years, 1 breast cancer related death is avoided at 15 years [23] . Punglia et al. [24] emphasize the importance of a careful selection of patients for BCT as this BCT  889  813  661  530  408  315  240  159  102  54  MAS 562  466  342  249  180  136  95  60  24  5 Number of patients at risk P=0.0831 strategy leads to a decrease in breast cancer-related and overall mortality. Although the proportion of local relapses is higher after BCT, studies among young women show no difference in distant recurrence-free survival [15, 17] .
Neither did we find a significant difference, with a distant recurrence-free survival at 10 years of 67.0% after mastectomy and 71.1% after BCT. The multivariate analysis also showed no difference in distant recurrence-free survival after treatment with BCT and mastectomy. Results from retrospective studies are harder to interpret than results from randomized controlled studies, because of a possible bias due to differences in baseline characteristics and the selection of treatments. However, randomized studies were not able to give a definitive answer and new randomized controlled trials are hard to imagine. Our study is the largest study so far with long-term follow-up comparing the outcome after BCT and mastectomy in young women with early-stage breast cancer. Moreover, it is population-based and follow-up was meticulously done. One could argue that the poor local control after BCT is dominated by a group of patients treated rather shortly after the introduction of BCT in the Netherlands, when less attention was given, for example, to preoperative imaging of the tumor and inking of surgical margins (both invasive and DCIS). Fact is however, that a poor local tumor control was also observed in the patients treated in the second period (1994-1999) ( Table 2) . Fortunately, in the period 2000-2005, we observed a clear trend towards improved local control. There are several factors which could have contributed to this improvement. First of all, the awareness of different risk factors for local relapse after BCT, not only may have led to a more stringent selection of patients for BCT [25] , but also to a certain reluctance towards treating young women with BCT. Over time, the BCT rate decreased from 69 to 55%. Secondly, improvements in the locoregional treatment of breast cancer have taken place over the past decades. However, the most important reason for the better local control is the increased use of adjuvant systemic treatment. Table 2 shows a significant increase in local tumor control over time for patients treated with BCT. This can be largely explained by the increasing proportion of node-negative patients receiving adjuvant systemic therapy. In the period 1994-1999 15% of node negative patients received adjuvant systemic therapy, which had increased to 60% in the period 2000-2005. Apart from this, we did not notice an additional influence of second or third generation regimens over first generation regimens on the local relapse rate. Our results, showing the importance of adjuvant systemic treatment and its potential to decrease the risk of local relapse, are in line with other studies [7, 13, 23, [26] [27] [28] .Patient and tumor-related risk factors for local relapse besides young age, are high tumor grade, positive excision margin, and lymphovascular invasion (LVI). In our series, 94% of the patients had a reported complete tumor excision and of all local relapses, 92% occurred in patients with a microscopically complete excision. This is in line with the results of a study by Jones et al. [10] , in which only young age, grade 3, the lack of systemic treatment and the omission of a boost dose were found to be independent prognostic factors for local relapses after BCT. Data on LVI and tumor grade were not or only partly available in our material. Local control is a result of the interaction between tumor remnants, treatment and tumor biology. An ipsilateral breast tumor recurrence (IBTR) can be a new primary tumor or the result of outgrowth of a tumor remnant in the treated breast, a so called true recurrence. New primary tumors often appear later in time and there is some proof that they have a more favorable prognosis than true recurrences. Molecular clonality assays can help to establish the type of IBTR [29, 30] , but larger studies are needed to draw conclusions about their potential prognostic and therapeutic value.
Recently, studies of tumor biology by gene expression micro-array technology have demonstrated patterns correlating with breast cancer in young women [31] and even local relapses in young women [32] . However, this new technology is not yet robust enough for clinical use with regard to local treatment decisions until results from ongoing prospective clinical trials are available. Genetic alterations in histologically normal tissue adjacent to the breast tumor, such as chromosomal instability and DNA hypermethylation, could also play a role in the development of local relapse [33, 34] .
For the patients in our study information about BRCA1/ 2 status was largely unknown. Population-based data indicate that approximately 10% of the breast cancers in women younger than 40 years are related to a BRCA1 or BRCA2 mutation [35] . Although women who carry BRCA mutations have a very high risk of developing breast cancer, there is no convincing evidence that their risk of developing local relapse after BCT is significantly different from the risk in non-carriers [36] [37] [38] . The risk of developing a contralateral breast cancer is, on the other hand, much higher than in non-carriers [36] [37] [38] .
The categorisation into breast cancer subtypes, based on the combination of hormonal receptor status and HER-2 status, may be predictive for recurrence risks and survival. Kyndi et al. [39] found a significantly lower locoregional recurrence rate and a significant survival improvement in hormone receptor positive patients treated with mastectomy and radiation therapy whereas in triple negative and hormone receptor negative patients the benefit of radiotherapy was much less pronounced. In HER-2 positive patients, trastuzumab reduced the risk of locoregional recurrence by 57% [40] .
In summary, local control after BCT in patients B40 years is significantly worse than after mastectomy with local relapses continuing to occur during long-term followup. Local relapses might negatively influence the long-term survival of patients with breast cancer, although we were unable to demonstrate this. Adjuvant systemic therapy has been the main contributor to the observed improvement of local control over the past decades. Nevertheless, the local relapse rate remains approximately 1% per year, which underlines the necessity of improvement and continuation of follow-up. Whether the marked reluctance against BCT in young women is less appropriate with current, more potent systemic treatment has to be confirmed. The biggest challenge still remaining is to define the most appropriate local treatment for each individual patient by establishing new predictors for local relapse after BCT.
